As most of you know, continuous glucose monitoring (CGM) technology is a valuable diabetes management tool clinically proven to provide better glucose control. While 95% of private health plans cover the technology, Medicare does not, denying Americans age 65 and older access to this critical technology.
For more than a year, Medtronic, along with a coalition of patient advocacy groups, professional societies, and other companies, has been working to address this issue. In July, we shared the exciting news that Senators Susan Collins and Jeanne Shaheen introduced legislation (S. 2689) to provide access to CGM for Medicare patients. If you have taken action on the Senate bill, thank you!
We’re pleased to share this important update with you: Representatives Tom Reed, Dianna DeGette, and Ed Whitfield have introduced companion legislation into the House of Representatives! What does this mean? Well, in order for a bill to become a law, it must be passed in both the Senate and the House before going to the President to sign or veto. So, this “companion bill”, which is nearly identical in content with a new number (H.R. 5644), is a key step in the legislative process.
We need your help! Please contact your Representatives today, and urge them to co-sponsor this House legislation! In addition, if your Senator hasn’t co-sponsored yet, contact him/her as well.
To find your members of Congress and easily contact them, click here.
Thank you for your support of this important issue for the diabetes community. If you have any questions, feel free to ask me in the comments below.
 Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010; 363:311–320.
 Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomized controlled trial. Diabetologia. 2012;55:3155-3162.
IMPORTANT SAFETY INFORMATION
– Medtronic Diabetes insulin infusion pumps, continuous glucose monitoring systems and associated components are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks associated with the use of these systems.
– Successful operation of the insulin infusion pumps and/or continuous glucose monitoring systems requires adequate vision and hearing to recognize alerts and alarms.
Medtronic Diabetes Continuous Glucose Monitoring (CGM) Systems
– The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a home glucose meter. A confirmatory fingerstick is required prior to treatment.
– Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected.
For more information, please visit www.medtronicdiabetes.com/importantsafetyinformation.
, cgm advocacy
, cgm coverage
, diabetes advocacy